Summary of Alkermes Conference Call Company Overview - **Company**: Alkermes - **Event**: 2026 TD Cowen Healthcare Conference - **Key Speaker**: Richard Pops, Chairman and CEO Industry Focus - **Primary Industry**: Sleep Medicine - **Key Products**: Alixorexton, LUMRYZ, Avadel acquisition Core Points and Arguments 1. **Business Transition**: Alkermes has undergone significant changes in 2025, solidifying its position in the sleep medicine market, particularly with the orexin franchise and the acquisition of Avadel [2][3] 2. **Market Position**: The company is now a major player in the sleep medicine market, preparing for the launch of alixorexton, supported by a strong and cash-generative base business [3] 3. **Acquisition Rationale**: The acquisition of Avadel was strategic, enhancing the company's presence in sleep centers and preparing for the alixorexton launch, which is expected to shift the launch curve positively [4][7] 4. **Unmet Needs in Narcolepsy**: There is a significant gap between the prevalence of narcolepsy (approximately 200,000 patients in the U.S.) and those treated (about 80,000), indicating a large market opportunity [15] 5. **Orexin Compounds**: The company is investigating the ideal dosing for orexin agonists, with promising data from Phase 2 studies indicating safety and efficacy [17][18] 6. **Phase 3 Program**: Alkermes is initiating a Phase 3 program with three studies focused on NT-1 and NT-2, with primary endpoints including the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) [24][25] 7. **Cognitive and Fatigue Outcomes**: The company has observed significant improvements in cognitive complaints and fatigue in patients, which are critical for treatment success [56][57] Additional Important Content 1. **Base Business Strength**: Alkermes has transformed from a royalty-based business to a proprietary products business, with expectations of $1.4 billion from proprietary products in 2026 [59][60] 2. **Commercial Strategy**: The acquisition of Avadel is expected to broaden the commercial portfolio and increase profitability, allowing for aggressive investment in the pipeline [60][61] 3. **Future Opportunities**: Alkermes is exploring additional indications for orexin drugs, including ADHD and fatigue, with initial proof of concept data expected soon [46][48] 4. **Side Effect Profile**: The orexin compounds have a mild to moderate side effect profile, with insomnia being the most common, which tends to diminish over time [39][40] 5. **Business Development**: The company is open to tuck-in business development deals that leverage its clinical and scientific capabilities but is currently focused on executing its late-stage and earlier-stage programs [63][64] This summary encapsulates the key points discussed during the conference call, highlighting Alkermes' strategic direction, market opportunities, and product development plans.

Core Insights - Alkermes plc (ALKS) reported adjusted earnings of 46 cents per share for Q4 2025, surpassing the Zacks Consensus Estimate of 43 cents, but down from $1.04 per share in the same quarter last year [1] - Total revenues for Q4 were $384.5 million, a decrease of 10.6% year over year, primarily due to lower manufacturing and royalty revenues, yet still beating the Zacks Consensus Estimate of $380 million [2] - Despite the earnings beat, ALKS shares fell by 7% following the announcement, with a 7.1% increase in share price over the past six months compared to a 23% rise in the industry [2] Financial Performance - Alkermes' proprietary product sales grew by 2.5% year over year to $315.5 million in Q4, driven by strong demand for Lybalvi, aligning with management's guidance of $300-$320 million [4] - Sales of Vivitrol decreased by 7.5% year over year to $124.1 million, while Aristada sales increased by 0.6% to $97.2 million, both exceeding their respective Zacks Consensus Estimates [7] - Lybalvi generated sales of $94.1 million, up 22.2% year over year, with total prescriptions increasing by 25% [8] Revenue Breakdown - Manufacturing and royalty revenues fell approximately 43.4% year over year to $69.1 million, with specific contributions from Biogen's Vumerity at $27.6 million and royalties from Xeplion and certain Invega products at $31.3 million [9] - For the full year 2025, Alkermes reported revenues of $1.48 billion, reflecting a 5.1% decline year over year, with earnings from continuing operations at $1.43 per share, down from $2.20 [11] 2026 Guidance - Alkermes expects total revenues for 2026 to be in the range of $1.73-$1.84 billion, primarily driven by net sales of proprietary products projected at $1.52-$1.60 billion [12] - Specific sales forecasts include Vivitrol at $460-$480 million, Aristada at $365-$385 million, and Lybalvi at $380-$400 million [12] - The company anticipates research and development expenses of $445-$485 million and selling, general, and administrative expenses of $890-$930 million [13] Leadership Changes - Alkermes announced that CEO Richard Pops will retire on July 31, 2026, with Blair Jackson appointed as the new CEO effective August 1, 2026 [14] Recent Developments - The company completed the acquisition of Avadel Pharmaceuticals, adding the FDA-approved product Lumryz to its portfolio, which is indicated for narcolepsy [15][16] - Alkermes plans to initiate Phase III studies for alixorexton, a novel treatment for narcolepsy, in Q1 2026 [17]

Core Viewpoint - Alkermes is positioning itself for growth in 2026 following a strong performance in 2025, with a focus on expanding its commercial platform and advancing its orexin pipeline, particularly through the recent acquisition of Avadel and the development of alixorexton [5][21]. Financial Performance - For 2025, Alkermes reported GAAP net income of $241.7 million and adjusted EBITDA of $394.0 million, ending the year with $1.3 billion in cash and total investments [2]. - Total revenues for 2025 were nearly $1.5 billion, driven by proprietary product net sales of approximately $1.2 billion, which grew 9% year over year [4]. Revenue Guidance for 2026 - Alkermes guided total revenues for 2026 between $1.73 billion and $1.84 billion, with proprietary product net sales expected to be between $1.52 billion and $1.60 billion [1]. - Manufacturing and royalty revenues are projected to be between $210 million and $240 million, reflecting the expiration of certain XEPLION royalties [1]. Expense Management - Cost of goods sold for 2026 is expected to be between $365 million and $385 million, influenced by purchase price accounting for LUMRYZ inventory [6]. - R&D expenses are projected to be between $445 million and $485 million, while SG&A expenses are expected to be between $890 million and $930 million, including one-time transaction costs related to the Avadel acquisition [7]. Product Performance - VIVITROL net sales for 2025 were $467.9 million, with a guidance of $460 million to $480 million for 2026 [10]. - ARISTADA net sales were $370.0 million in 2025, with a guidance of $365 million to $385 million for 2026 [11]. - LYBALVI saw a 24% increase in net sales to $346.7 million in 2025, with a guidance of $380 million to $400 million for 2026 [12]. - LUMRYZ generated approximately $279 million in net sales in 2025, with a guidance of $350 million to $370 million for 2026 [13]. Pipeline Developments - Alixorexton is expected to enter phase III trials in narcolepsy, with a detailed program planned [15][16]. - The company is also advancing two additional orexin 2 receptor agonists in phase I studies, with plans for further development in ADHD and fatigue associated with multiple sclerosis and Parkinson's disease [18]. Leadership Transition - A leadership transition is underway, with CEO Richard Pops set to step down and COO Blair Jackson taking over, while Pops will remain as chairman [21].

Financial Data and Key Metrics Changes - In 2025, total revenues reached nearly $1.5 billion, with a year-over-year growth of 9% driven primarily by proprietary products generating approximately $1.2 billion in net sales [9][10] - GAAP net income for the year was $241.7 million, with adjusted EBITDA of $394 million [11][18] - The company ended the year with $1.3 billion in cash and total investments [12] Business Line Data and Key Metrics Changes - VIVITROL net sales were $467.9 million, reflecting a 2% growth year-over-year [24] - ARISTADA net sales reached $370 million, showing a 7% growth year-over-year [26] - LYBALVI net sales grew 24% year-over-year to $346.7 million [27] - LUMRYZ generated approximately $279 million in net sales in 2025, with around 3,500 patients on therapy by year-end [30] Market Data and Key Metrics Changes - The company expects total revenues for 2026 to be in the range of $1.73 billion to $1.84 billion, driven primarily by proprietary products [13][14] - Manufacturing and royalty revenues for 2026 are anticipated to be between $210 million and $240 million [15] - The estimated market for oxybate-eligible patients with narcolepsy is around 50,000, indicating significant growth potential for LUMRYZ [32] Company Strategy and Development Direction - The acquisition of Avadel is seen as a strategic milestone, enhancing the company's entry into the commercial sleep medicine market and providing a platform for launching alixorexton [6][12] - The company plans to initiate the phase III Brilliance program for alixorexton in narcolepsy, with expectations of significant advancements in treatment [34] - The focus remains on operational discipline, efficient capital allocation, and investing in high-potential growth drivers, particularly in the orexin portfolio [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and the potential for growth in 2026, emphasizing the importance of the Avadel acquisition [12][23] - The company is committed to delivering shareholder growth and maintaining a strong cash flow positive profile despite expected GAAP net losses due to accounting for the acquisition [18] - Management highlighted the importance of ongoing clinical trials and the potential for alixorexton to transform narcolepsy management [40] Other Important Information - The company plans to initiate a multi-dose phase Ib study for ALKS 7290 in ADHD and a phase IIa study for ALKS 4510 in fatigue associated with neurodegenerative disorders [38][39] - The transition of CEO leadership from Richard Pops to Blair Jackson is set to occur in the summer, with Pops continuing as chairman [40] Q&A Session Summary Question: Phase III trial design and AE profile - Management indicated that the orexin 2 receptor agonists are generally well tolerated, and the split dosing is designed to maximize efficacy while minimizing side effects [44][46] Question: Potential synergies from Avadel acquisition - The integration of the Avadel commercial team is progressing well, with expectations of future synergies as the company prepares to launch alixorexton [48][49] Question: Evidence needed for payer reimbursement for both oxybates and orexin agonists - Management believes that both treatments will be important for certain patients, and they plan to generate data to support reimbursement for this cohort [51][52] Question: Internal bar for ESS in LUMRYZ phase III - Management expects the data from the IH study to mirror previous successful programs, with key secondaries being important for prescriber confidence [56][60] Question: Current understanding of NT1 versus NT2 and IH dynamics - Management noted that the narcolepsy market represents a significant opportunity, with ongoing efforts to understand the IH market better [66]

Financial Data and Key Metrics Changes - In 2025, Alkermes generated total revenues of nearly $1.5 billion, with a year-over-year growth of 9% driven primarily by proprietary products, which generated approximately $1.2 billion in net sales [9][10] - GAAP net income for the year was $241.7 million, with EBITDA of $285.6 million and adjusted EBITDA of $394 million [11] - The company ended the year with $1.3 billion in cash and total investments [12] Business Line Data and Key Metrics Changes - VIVITROL net sales were $467.9 million, ARISTADA net sales were $370 million, and Lybalvi net sales were $346.7 million for 2025 [9][10] - For 2026, total revenues are expected to be in the range of $1.73 billion to $1.84 billion, primarily driven by proprietary products [13] - LUMRYZ, launched in 2023, generated approximately $279 million in net sales in 2025, with expectations of $350 million to $370 million for 2026 [27][30] Market Data and Key Metrics Changes - The company anticipates manufacturing and royalty revenues in the range of $210 million to $240 million for 2026, reflecting the expiration of certain XEPLION royalties [14] - The estimated market for narcolepsy includes about 200,000 patients in the US, with approximately 80,000 currently being treated [63] Company Strategy and Development Direction - The acquisition of Avadel is seen as a strategic step to enter the commercial sleep medicine market and enhance the company's product portfolio [6][12] - The company plans to advance its orexin portfolio, including alixorexton, which is expected to enter Phase 3 trials for narcolepsy [7][31] - The focus remains on operational discipline, efficient capital allocation, and investing in long-term growth opportunities [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and the potential for growth in 2026, despite anticipated GAAP net losses due to accounting related to the Avadel acquisition [17] - The company is committed to delivering shareholder growth and maintaining a strong cash flow positive profile [20][21] Other Important Information - The transition of CEO from Richard Pops to Blair Jackson is planned for summer 2026, with Pops continuing as chairman [38] - The company is focused on integrating the Avadel team and leveraging their expertise in sleep medicine [29] Q&A Session Summary Question: Phase 3 trial design and AE profile - Management indicated that the orexin 2 receptor agonists have a favorable AE profile and that split dosing is designed to maximize efficacy while minimizing side effects [42][43] Question: Potential synergies across sales forces - The integration of the Avadel commercial team is expected to enhance the company's presence in sleep medicine, with no immediate overlap with the psychiatry sales force [45][46] Question: Evidence needed for payer reimbursement for both drugs - Management believes that both orexin agonists and oxybates will serve different patient needs, and data will be generated to support reimbursement for both [48][49] Question: Internal bar for ESS in LUMRYZ phase 3 - Management expects the data from the IH study to mirror previous successful programs, with key secondaries being important for prescriber confidence [54][58] Question: Current understanding of NT1 vs NT2 and IH dynamics - The company acknowledges a significant unmet need in the IH market and plans to wait for phase 2 data before initiating phase 3 discussions with the FDA [60][63] Question: Plans to study LUMRYZ with oxybate - Management sees potential benefits for patients using both treatments and plans to build evidence for reimbursement purposes [67][69] Question: Field force strategy for LUMRYZ - The current sales force is deemed right-sized to target the oxybate-eligible patient segment, with ongoing monitoring of market dynamics [72][74] Question: SG&A spend beyond 2026 - Management indicated that one-time transaction costs will not carry over, and future spending will be controlled with potential synergies from the Avadel acquisition [76][78]

Financial Data and Key Metrics Changes - In 2025, Alkermes generated total revenues of nearly $1.5 billion, with a year-over-year growth of 9% in proprietary product sales, amounting to approximately $1.2 billion in net sales [7][8] - The company recorded GAAP net income of $241.7 million, EBITDA of $285.6 million, and adjusted EBITDA of $394 million for the year [10] - For 2026, total revenues are expected to be in the range of $1.73 billion to $1.84 billion, driven primarily by proprietary product net sales projected between $1.52 billion and $1.6 billion [12] Business Line Data and Key Metrics Changes - VIVITROL net sales for 2025 were $467.9 million, reflecting a 2% growth year-over-year, with expectations for 2026 net sales in the range of $460 million to $480 million [22][23] - ARISTADA net sales were $370 million in 2025, showing a 7% growth year-over-year, with projected 2026 net sales between $365 million and $385 million [24][25] - Bupropion net sales grew 24% year-over-year to $346.7 million in 2025, with expectations for 2026 net sales in the range of $380 million to $400 million [26] Market Data and Key Metrics Changes - LUMRYZ, launched in 2023, generated approximately $279 million in net sales in 2025, with a significant opportunity to expand the patient base as there are an estimated 50,000 oxybate-eligible patients with narcolepsy [27][29] - The company expects LUMRYZ total revenue for 2026 to be in the range of $350 million to $370 million, with an additional $315 million to $335 million expected for the remainder of the year following the acquisition of Avadel [29] Company Strategy and Development Direction - The acquisition of Avadel is seen as a strategic milestone, enhancing Alkermes' entry into the commercial sleep medicine market and providing a platform for the potential launch of alixorexton [4][11] - The company plans to advance its orexin portfolio, including alixorexton, which is expected to enter Phase 3 trials for narcolepsy, and develop ALKS 7290 and ALKS 4510 for ADHD and fatigue associated with neurodegenerative disorders [5][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and the potential for growth in 2026, emphasizing operational discipline and efficient capital allocation [20][21] - The management team highlighted the importance of the upcoming Phase 3 trials for alixorexton and the integration of Avadel's commercial capabilities as key drivers for future success [30][37] Other Important Information - The company ended 2025 with $1.3 billion in cash and total investments, positioning it well for future growth and debt management following the acquisition [11] - Management announced a leadership transition, with Blair Jackson set to take over as CEO, indicating a commitment to continue the company's growth trajectory [37] Q&A Session Summary Question: Regarding the Phase 3 trial design and AE profile - Management indicated that the orexin 2 receptor agonists have a favorable AE profile and that the split dosing is designed to maximize efficacy while minimizing side effects [41][42] Question: Potential synergies between sales forces post-Avaldel acquisition - Management expressed excitement about the integration of the Avadel team and noted that while there is currently little overlap, future synergies are anticipated as the company prepares to launch alixorexton [44][45] Question: Evidence needed for payers to reimburse both oxybates and orexin agonists - Management explained that both treatments may be necessary for certain patients, and they plan to generate data to support the use of both medications [47][48] Question: Internal benchmarks for ESS in the LUMRYZ Phase 3 trial - Management stated that they expect the data from the upcoming study to mirror previous successful profiles and emphasized the importance of secondary endpoints [52][56] Question: Development plans for Valiloxybate - Management indicated that they are moving forward aggressively with Valiloxybate and will assess the need for additional studies based on early data [84][85]

Company Overview - Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company focused on developing and selling medicines for schizophrenia, bipolar I disorder, and addiction to alcohol or opioids [2]. Recent Developments - On January 6, Alkermes announced that the FDA granted Breakthrough Therapy designation to its alixorexton therapy for narcolepsy type 1, following positive results from phase 1 and phase 2 studies [2]. - The clinical trial involved 92 patients and demonstrated that the oral orexin 2 receptor agonist achieved its primary endpoint, showing statistically significant, dose-dependent improvements in wakefulness [2]. - Craig Hopkinson, M.D., emphasized that alixorexton could significantly improve treatment for narcolepsy type 1, addressing unmet medical needs in the community [2]. - The company plans to advance alixorexton into phase 3 development later this quarter [2]. Market Sentiment - Jim Cramer expressed skepticism about Alkermes, suggesting it is a hold, possibly a weak one, indicating a lack of strong recommendation for the stock [1].

Core Insights - Alkermes (ALKS) has received Breakthrough Therapy Designation from the FDA for alixorexton, an oral orexin 2 receptor agonist, aimed at treating narcolepsy type 1 (NT1) [1][7] - The Breakthrough Therapy designation is designed to expedite the development and review of therapies for serious diseases with unmet medical needs [1] Company Developments - Alixorexton's Breakthrough Therapy designation is based on positive data from the phase I and phase II Vibrance-1 study, which showed significant improvements in wakefulness compared to placebo [3] - The Vibrance-1 study met its primary endpoint, demonstrating dose-dependent improvements in wakefulness as measured by the Maintenance of Wakefulness Test [3][4] - Treatment with alixorexton also significantly reduced excessive daytime sleepiness at week six, as measured by the Epworth Sleepiness Scale [4] - Alkermes plans to initiate a global phase III program for alixorexton in Q1 2026 [7][10] Market Context - Over the past year, Alkermes' shares have increased by 1.3%, while the industry has seen a rise of 14.2% [2] - Alixorexton is also being studied for narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), with positive data from the phase II Vibrance-2 study for NT2 announced in November 2025 [8][10] - The Vibrance-2 study showed statistically significant improvements in wakefulness and reductions in excessive daytime sleepiness for NT2 patients [8]

Group 1 - Alkermes plc (NASDAQ:ALKS) is considered a promising mid-cap healthcare stock under $50, with a consensus of 11 Buy ratings and 4 Holds from 15 analysts, indicating a median 1-year price target of $46.17, representing a 62.3% upside potential [1] - The company plans to acquire Avadel, which has a topline of approximately $275 million, as part of its strategy to enter the hypersomnolence market and launch alixorexton, an oral drug for complex sleep disorders [2] - Analyst David Amsellem from Piper Sandler reaffirmed a Buy rating for Alkermes with a price target of $45, suggesting more than 58% upside potential for investors [3] Group 2 - Alkermes is a biopharmaceutical company focused on developing and commercializing innovative medicines for neurological disorders, utilizing proprietary technologies for formulations aimed at psychiatric conditions [4]

Core Viewpoint - Alkermes plc acknowledges the announcement by Avadel Pharmaceuticals plc regarding a potential acquisition offer from H. Lundbeck A/S for all issued and to be issued ordinary shares of Avadel [1][2]. Group 1: Transaction Agreement Details - The Transaction Agreement stipulates that Avadel cannot terminate the agreement to pursue a superior proposal unless the board determines that doing so is consistent with its fiduciary duties and that the Lundbeck offer qualifies as a superior proposal [3]. - Avadel must notify Alkermes in writing at least five business days prior to taking any action related to the Lundbeck offer and must engage in good faith discussions with Alkermes regarding any amendments to the Transaction Agreement [3]. Group 2: Future Announcements - Alkermes will make further announcements as appropriate regarding the situation and any developments related to the potential acquisition [4].